Recurrent_4623643  Acute_Lymphocytic_Leukemia_114054908  ( ALL_114054908 ) patients_110250423  usually_3107782  do not_324548  benefit_22268916  from additional_451524  chemotherapy_1654008  alone_38625 .
If possible_41886604 , they should receive_22189688   reinduction  chemotherapy_1654008 , followed_22688832  by allogeneic_42681006  bone_marrow_15222547  transplant_15513505  (alloBMT).
Alternatively_363479 , patients_110250423  with recurrent_4623643   ALL_114054908  may benefit_22268916  from participation_11223427  in new_42141686  clinical_trials_1780823  of alloBMT, immune_system_15393243  agents_19059148 , and chemotherapeutic_42779945  agents_19059148 , or low_41259112 dose_13191991  radiotherapy_1694498 , if the cancer_114051451  recurs_2339381  throughout the body_15154650  or CNS_15412828 .
Chronic_Lymphocytic_Leukemia_114055518  ( CLL_114055518 ) is_22579744  probably_3139422  incurable_41034424  by present_41793279  treatments_1650240 .
But, fortunately_342117 , a large_41434452  group_129714  of  CLL_114055518  patients_110250423  do not_324548  require_22602586  therapy_1652939 .
Studies_17119574  suggest_2921281  that people_17834515  with Stage_113753838  A  CLL_114055518  (that is, individuals_17626  who have_22182934  fewer_41612560  than three_42262966  areas_15160192  of enlarged_4584087  lymphoid_tissue_15224806 ) do not_324548  benefit_22268916  from early_4851244  treatment_1650240 .
Most_41613064  oncologists_110222543  base_2629468   CLL_114055518  treatment_1650240  upon both the stage_115089620  and symptoms_114108771  of the patient_110250423 .
For_example_3160083 , in older_41703749  patients_110250423  (60 + years_115004692 ) who have_264628  low_41259112 risk_114349152  early_4851244  stage_115089620  disease_113883821  (Rai Stage 0 ) a conservative_41587247  "watch_22109022  and wait_22612588 " approach_1927464  may be taken_22575056 .
By contrast_113671859 , older_41703749  individuals_17626  with  CLL_114055518 related_42040999  complications_113887502  or more_3100048  advanced_4857679  disease_113883821  (Rai Stage III or IV) may benefit_22268916  from chemotherapy_1654008  and treatment_1650240  with a corticosteroid_114557280  (eg_3160083 , prednisone_114559089 , prednisolone_114558863 ).
Corticosteroids_114557280  are_22579744  firstline agents_114584006  for people_17834515  in whom the immune_systems_15393243  has been altered_2123976  by  CLL_114055518 . 
 CLL_114055518  may cause_21630835  autoimmune_42736065  syndromes_114113194  in which the patient_110250423  immune_system_15393243  attacks_219756  and destroys_21550911  his or her own_41831352  blood_cells_15381783 .
When the red_blood_cells_15386585  are affected_219468 , the condition is_22579744  
known_as_42511488  immunohemolytic anemia, characterized_22671919  by decreased_4920499  numbers_15061203  of red_blood_cells_15386585 , which may cause_21630835  fatigue_113830227 , dizziness_114181180 , and shortness_of_breath_114178789 .
When the blood_platelets_114826389  are affected_219468 , it is called_21018451  immunemediated thrombocytopenia, in which a decreased_4920499  numbers_15061203  of platelets_114826389  may lead_22610448  to bleeding_114097385 .
For younger_41706638  patients_110250423  who are experiencing_22088655  symptoms_114108771 , the physician_19872125  may consider_22146761  early_4851244  chemotherapy_1654008 , plus allogeneic_42681006  or autologous_41267312  bone_marrow_15222547  transplantation_1682970  (alloBMT; autoBMT).
If the patient_110250423  experiences_22088655  blood_15335196  flow_1325637  problems_114219078  caused_21630835  by high_41257379  numbers_15061203  of leukemia_114054437  cells_16300  in the circulation_111274325 , the physician_19872125  may recommend_2865882  leukapheresis, also_347757  known_as_42511488  apheresis_1643111 , to separate_out_21445957  white_blood_cells_15382474 , prior to chemotherapy_1654008 .
Symptoms_114108771  that are_22579744  related_to_42040999  enlargement_1361798  of the lymph_nodes_15363916  in one_42262724  area_15160192  or an overgrown_2229786  spleen_15269161  may be treated_277958  by localized_41478140 , low_41259112 dose_13191991  radiotherapy_1694498  or surgical_41215539  management_11117935  by splenectomy_1677060  (removal_1387602  of the spleen_15269161 ).
If leukemia_114054437  has invaded_21216125  the lymph_nodes_15363916  at many_41607490  different_42141357  sites_18502657 , total_4541797  body_15154650  irradiation_1694498  (TBI) may be needed_22602586 .
People_17834515  with intermediate_41055260  or advanced_4857679  disease_113883821  may be helped_22523332  by participation_11223427  in a clinical_trial_1780823 .
At the present_41793279  time_17209466 , clinical_trials_1780823  are being conducted_22421850  using_21147708  immunologic_42831830  compounds_114622879  (eg_3160083 , interferons_13539958 , monoclonal_antibodies_114832211 ) as well as new_42141686  chemotherapeutic_42779945  agents_114584006  (eg_3160083 , bryostatin, dolastatin 10 , and PSC 83   a cyclosporine drug_13213810  given_22287600  with chemotherapy_1654008  to overcome_21097772  drug_13213810  resistance_15152161 ).
Acute Myelogenous Leukemia (AML) is_22579744  most_3112597  common_41010117  for adults_19469104 ; more men_110133569  than women_110626312  are affected_219468 .
Many_41607490  different_42135760  chemotherapeutic_42779945  plans_15823699  are_22579744  available_4203394  for the treatment_1650240  of AML.
 Overall , the strategy_15830479  is_22579744  to control_22486168  bone_marrow_15222547  and systemic_41478850  (whole_4541319 body_15154650 ) disease_113883821  while offering_22275070  specific_41145617  treatment_1650240  for the central_nervous_system_15412828  (CNS_15412828 ), if involved_41569119 .
In_general_341817 , most_41613064  oncologists_110222543  rely_2680280  on combinations_17855596  of drugs_13213810  for the initial_41052110 , induction_1234711  phase_115089620  of chemotherapy_1654008 .
 Such  combination_17855596  chemotherapy_1654008  usually_3107782  offers_22275070  the benefits of early_4851244  remission_17318981  (lessening_17255090  of the disease_113883821 ) and a lower_41259112  risk_114349152  of disease_113883821  resistance_15152161 .
Consolidation_11221778  or "maintenance_1263752 " treatments_1650240  may be given_22294885  to prevent_22428989  disease_113883821  recurrence_17242696  once_3182502  remission_17318981  has been achieved_22501902 .
Consolidation_11221778  treatment_1650240  often_335856  entails_22609808  a repetition_11004630  of induction_1234711  chemotherapy_1654008  or the intensification_1370313  chemotherapy_1654008  with added_2179714  drugs_13213810 .
By contrast_113671859 , maintenance_1263752  treatment_1650240  involves_22610758  drug_13213810  doses_13191991  that are_22579744  lower_41259112  than those administered_280270  during the induction_1234711  phase_115089620 .
In_addition_346444 , specific_41145617  treatment_1650240  plans_15823699  may be used_21147708 , depending_22638691  on the type_15767228  of leukemia_114054437  that has been diagnosed_2637804 .
Whatever the plan_15823699 , it is_22579744  important_41323836  for the patient_110250423  to understand_2581759  the treatment_1650240  that is being given_22287600  and the decisionmaking_15717114  process_11009596  behind the choice_1158063 .
Initial_41052110  treatment_1650240  of AML usually_3107782  begins_22583241  with induction_1234711  chemotherapy_1654008  using a combination_17855596  of drugs_13213810  such as daunorubicin (DNR), cytarabine (araC), idarubicin, thioguanine_14372503 , etoposide, or mitoxantrone, anabolic_steroids_114912783 .
Patients_110250423  with newly_3113589  diagnosed_2637804  disease_113883821  also_347757  may be considered_22146761  for stem_cell_15538367  transplantation_1682970  (SCT), either from the bone_marrow_15222547  or other_42140352  sources_18389765 .
Allogeneic_42681006  bone_marrow_15222547  transplant_15513505  (alloBMT) is_22579744  reserved_42057593  primarily_374239  for patients_110250423  under 55_42267988  years_115004692  of_age_41704047  who have_22182934  a compatible_4532877  family_17968033  donor_19876994 .
Approximately_37040  half_113556027  of newly_3113589  diagnosed_2637804  AML patients_110250423  are_22579744  in this age_group_17835861 , with 75_42269907 % achieving_22501902  a complete_4546929  remission_17318981  (CR) after induction_1234711  and consolidation_11221778  therapy_1652939 .
Allogeneic_42681006  bone_marrow_15222547  transplant_15513505  is_22579744  available_4203394  for about_37040  15_42264143 % of all_42345966  patients_110250423  with AML.
Unfortunately_342632 , it is estimated_2664380  that only_34711  7_42263356 % of all_42345966  AML patients_110250423  will be cured_280923  using_21147708  this procedure_11009596 .
People_17834515  who receive_22189688  stem_cell_15538367  transplantation_1682970  (SCT, alloBMT) require_22602586  protective_41953804  isolation_11186990  in the hospital_13501793 , including_22607558  filtered_21445957  air_114645770 , sterile_42192141  food_120429 , and sterilization_1250167  of the microorganisms_11309923  in the gut_15465549 , until their total_4541797  white_blood_cell_15382474  (WBC) count_113417015  is_22579744  above 500_42274891 .
Treatment_1650240  of central_nervous_system_15412828  leukemia_114054437 , if present_41793279 , may involve_22610758  injection_1686265  of chemotherapeutic_42779945  drugs_13213810  (eg_3160083 , cytarabine or araC, methotrexate_13714267 ) into the areas_15160192  around the brain_15413129  and the spinal_cord_15435093 .
Once_3182502  the patient_110250423  is_22579744  in remission_17318981 , he or she will receive_22189688  consolidation_11221778  or maintenance_1263752  therapy_1652939 , 
for_example_3160083 , consolidation_11221778  therapy_1652939  with high_41257379 dose_13191991  araC (HDAC) with/without anthracycline drugs_13213810 ).
Elderly_41703749  AML patients_110250423  have_22182934  special_41146622  treatment_1650240  concerns_15759473 .
They may be_22579744  less_3100234  able_41740  to tolerate_22089886  the septicemia_114001486  (blood_poisoning_114001486 ) associated_42042200  with granulocytopenia_113885357 , and they often_335856  have_22182934  higher_41257379  rates_115085533  of myelodysplastic ('preleukemia') syndrome_114113194  (MDS).
Individuals_17626  who are_22579744  over age_114946104  75_42269907  or who have_22604841  significant_42238654  medical_41215333   conditions  can be treated_277958  effectively_3328528  with low_41259112 dose_13191991  araC.
High_41257379 dose_13191991   postinduction  chemotherapy_1654008  is_22579744  unlikely_41465532  to be tolerated_22089886  by elderly_41703749  patients_110250423 .
Until recently_3108293 , the treatment_1650240  plans_15823699  and responses_1846903  of children_19771320  with AML did not_324548  differ_22640699  much_359483  from those of adults_19469104 .
Yet new_42141686 , more_3100048  intensive_41566603  induction_1234711  and consolidation_11221778  treatments_1650240  have resulted_22608883  in higher_41257379  remission_17318981  rates_115085533  and prolonged_41491533  survivals_113776149 .
Many_41607490  induction_1234711  trials_1779545  have produced_21737120  good_41168164  results_17192761  using_21147708  combinations_17855596  of cytarabine (araC) plus an anthracycline (eg_3160083 , daunorubicin, doxorubicin_13196641 ).
In children_19771320  under 3_42262966  years_115004692  of_age_41704047 , the anthracycline used_21147708  for induction_1234711  should be chosen_2666555  with care_15546338 , since doxorubicin_13196641  produces_21737120  more_41611077  toxicity_14735461  and related_42040999  deaths_17254694  than daunorubicin.
Consolidation_11221778  therapy_1652939  is_22579744  complex_42252594 , but it should include_22607558  at_least_3105060  two_42262856  courses_18262401  of high_41257379 dose_13191991  araC (HDAC).
Children_19771320  who have_264628  hyperleukocytosis (too_347638  many_41607490  
white_blood_cells_15382474 ), especially_384750  monocytic M5  leukemia, have_22604841  a poor_41173827  prognosis_1150685 .
The challenge_113746930  of treating_277958  newly_3113589  diagnosed_2637804  
Chronic Myelogenous Leukemia (CML) is_22579744  to determine_2909540  the best_4248569  overall_41640778  strategy_15830479  to control_22486168  the disease_113883821 .
Leukapheresis, also_347757  known_as_42511488  a peripheral_4353938  blood_15335196  stem_cell_15538367  transplant_1682970 , with stem_cell_15538367   cryopreservation  (frozen_41119991  storage_1799763 ) prior to any_42344366  other_42140352  treatment_1650240 .
The patient_110250423  blood_15335196  is passed_through_22034871  a machine_13659195  that removes_2170552  the stem_cells_15538367  and then_3118752  returns_22288206  the blood_15335196  to the patient_110250423 .
 Leukapheresis  usually_3107782  takes_22246711  3_42262966  or 4_42263051  hours_115028658  to complete_2479055 .
The stem_cells_15538367  may or may not_324548  be treated_277958  with drugs_13213810  to kill_21312214  any_42344366  cancer_cells_15365106 .
The stem_cells_15538367  then_3118752  are stored_22259548  until they are transplanted_21517560  back_375503  into the patient_110250423 .
HLA (human leukocyte antigen) typing_2610888  of all_42345966  patients_110250423  under age_114946104  60_42268462 , as well as typing_2610888  of siblings_110435793 , parents_110244202 , and children_19771976 , if available_4203394 .
This procedure_11009596  will determine_2909540  whether a compatible_4532877  donor_19876994  is_22579744  available_4203394  for stem_cell_15538367  transplantation_1682970 .
 Pretreatment  fertility_113865290  measures_1170956  (eg_3160083 ,  cryopreservation  of semen_15339588  prior to treatment_1650240 ; completion_1207532  of a pregnancy_113859987  prior to treatment_1650240 ) in young_41706638  patients_110250423  who have not_324548  completed_2450821  their families_17968033 .
In_general_341817 , CML treatment_1650240  options_15719675  are divided_22443783  into two_42262856  groups_129714 : those that do not_324548  increase_2150700  survival_113776149  and those that do.
Chemotherapeutic_42779945  drugs_13213810  such as hydroxyurea (Hydrea) and busulfan (Myleran) can normalize_2463307  the blood_count_113417359  for a period_of_time_114914858 , but they do not_324548  increase_2153864  survival_113776149 .
They often_335856  are used_21147708  to control_22486168  blood_counts_113417359  in patients_110250423  who cannot undergo_22088655  SCT or who do not_324548  respond_2710443  to interferon_13539958  therapy_1652939  because of age_14868793  or medical_41215333  considerations_15749946 .
Gleevec, is_22579744  one of a new_42141686  class_17889030  of cancer_drugs_12697136  that disables_2507017  an abnormal_41654031  enzyme_114538863  in the cancerous_42680117  cell_16300 , kills_21312214  it, but leaves_2134595  healthy cells_16300  virtually_373379  untouched_477984 .
Other_42140352  cancer_114051451  therapies_1652939 , such as chemotherapy_1654008 , attack_219756  healthy cells_16300  as well as cancer_cells_15365106 , leaving_22705088  patients_110250423  with unpleasant_41865078  and often_335856  severe_41567378  side_effects_114120984 .
In June_115012596  of 2006 , the Food_and_Drug_Administration_18013935  (FDA_18013935 ) approved_2797994  the oral_42856828  tyrosine_114884878  kinase_114731164  inhibitor_114530515  dasatinib (Sprycel(tm)) to treat_277958  CML that does not_324548  respond_2710443  to other_42140352  therapy_1652939 .
One_42262724  treatment_1650240  that does impact_2134917  on CML survival_113776149  is_22579744  allogeneic_42681006  bone_marrow_15222547  transplantation_1682970 , the use_1933270  of high_41257379  dose_13191991  chemotherapy_1654008  and radiation_1694498  followed_22688832  by infusion_1319933  of a donor_19876994  bone_marrow_15222547 .
This procedure_11009596  removes_2565648  the chromosomal_43040813  abnormality_114309161  in a large_41434452  percentage_113636179  of patients_110250423  and for them is_22579744  curative_41212623 .
About_37040  20_42264613 % to 30_42265602 % of patients_110250423  taking_21145724  interferon_13539958  show_21005161  elimination_1391284  of the abnormal_41654031  chromosome_15374754  and improved_4252075  survival_113776149 .
Recent_41701904  findings_19146604  also_347757  suggest_2921281  that low_41259112 dose_13191991  cytarabine (araC), in combination with interferon_13539958 , may be_22579744  more_3100048  beneficial_41213093  than interferon_13539958  alone_38625 .
For patients_110250423  who do not_324548  respond_2710443  to interferon_13539958 , autologous_41267312  or allogeneic_42681006  stem_cell_15538367  transplantation_1682970  is_22579744  the only_42290770  alternative_15719675 .
Patients_110250423  with advanced_4857679 phase_115089620  disease_113883821  may be treated_277958  with cytotoxic_drugs_13125819 .
For_example_3160083 , individuals_17626  showing_22117319  myeloid_43095412  transformation_17258802  may be given_22294885  drugs_13213810  that are used_21147708  to induce_21629356  remission_17318981  in AML  that is, daunorubicin and cytarabine, with or without 6 thioguanine or etoposide.
 Blast cell  numbers_15061203  will be reduced_2424760  temporarily_388981 , but they will increase_2153864  again_341086  within 3_42262966  to 6_42263219  weeks_114970832 . 
Individuals_17626  showing_22117319  lymphoid_42916606  transformation_17258802  have_22182934  a slightly_337158  better_4251307  outlook_15869459 .
They are treated_277958  with drugs_13213810  used_21147708  in the management_11117935  of acute_lymphocytic_leukemia_114054908  ( ALL_114054908 )  that is, prednisone_114559089 , vincristine_14481324 , and daunorubicin, with or without Lasparaginase.
New_42141686  drugs_13213810  that are being studied_2636835  in clinical_trials_1780823  of CML include_22607558  homoherringtonine with interferonalpha (INFa), paclitaxel (Taxol), QS21  (a plant_116858  extract_114653307  that heightens_2427788  immune_responses_1848335 ), and amifostin (a chemical_114612110  that lessens_2436831  some_42343988  side_effects_114120984  of chemotherapy_1654008 ).
In_addition_346444 , clinical_trials_1780823  are evaluating_2673425  the potential_446761  benefits_15081982  of substances_119102  such as vaccines_14463717 , monoclonal_antibodies_114832211  (immunologic_42831830  substances_119102  that can direct_2740911  the patient_110250423  immune_system_15393243  to kill_21312214  cancer_cells_15365106 ), and hormones (eg, growth factors, interleukins).
Hairy cell leukemia (HCL) is_22579744  an incurable_41034424 , indolent_440708  
blood_disorder_114000853  in which mutated_2117607 , partly_37728  matured_41542400  B_cells_15384210  accumulate_22283208  in the bone_marrow_15222547 .
Hairy cell leukemia's name_16248892  is derived_2248424  from the shape_15005009  of the cells_16300 , which look_22113647  like they are_22579744  covered_41755623  with short_41488508 , fine_42308316 , hair_11880876 shaped_42227016  projections_13963788 .
Unlike any_42344366  other_42140352  leukemia_114054437 , HCL is characterized_22671919  by low_41259112  white_blood_cell_15382474  counts_113417015 .
Patients_110250423  with hairy cell leukemia who are_22579744  symptomfree typically_3128965  do not_324548  receive_22189688  immediate_41018447  treatment_1650240 .
Patients_110250423  of Hairy cell leukemia engage_22352377  in "watchful_498726  waiting_11049634 " with routine_42030748   blood work  and exams every_42346866  three_42262966  to six_42263219  months_115007086  to monitor_22143792  disease_113883821  progression_17343663  and identify_2611084  any_42344366  new_42141686  symptoms_114108771 . 
Treatment_1650240  is generally_3156864  considered_2682517  necessary_41637954  when the patient_110250423  shows_22117319  signs_114110919  and symptoms_114108771  such as low_41259112  blood_cell_15381783  counts_113417015 , frequent_41107882  infections_113986195 , unexplained_4979961  bruises_114098018 , anemia_114006964 , or fatigue_113830227  that is_22579744  significant_42238654  enough_3146900  to disrupt_2769609  the patient_110250423  everyday_41010454  life_113775382 .
Patients_110250423  who need_22602586  treatment_1650240 , which includes_22607558  most_3112597  newly_3113589  diagnosed_2637804  HCL cases_19753021 , usually_3107782  receive_22189688  either cladribine or pentostatin, which are_22579744  both in a class_17889030  of chemotherapeutic_42779945  drugs_13213810  known_as_42511488  purine analogs or nucleosides_114767401 .
In most_41613064  cases_19753021 , one_42262724  round_115087114  of treatment_1650240  will produce_21737491  a prolonged_41491533  remission_17318981 .
Other_42140352  treatments_1650240  include_22607558  rituximab infusion_1319933  or self_42879908 injection_1686265  with Interferonalpha.
In limited_41047449  cases_17208756 , the patient_110250423  may benefit_22268916  from splenectomy_1677060  (removal_1387602  of the spleen_15269161 ).
These treatments_1650240  are not_324548  typically_3128965  given_22287600  as the first_41050981  treatment_1650240  for a new_41700277  patient_110250423  because their success_161760  rates_113635302  are_22579744  lower_41259112  than cladribine or pentostatin.
In the short term, especially_384750  when neutrophil_15386172  counts_113417015  are_22579744  low_41259112 , many_41607490  patients_110250423  also_347757  take_21145724  antibiotics_12691801  until their white_blood_cell_15382474  counts_113417015  have recovered to normal_41652138  levels_15034128 .
Significant_42238654  research_1630686  into the causes_17226331 , diagnosis_1149750 , treatment_1650240 , and prognosis_1150685  of leukemia_114054437  is being done_21697549 .
Hundreds_113569316  of clinical_trials_1780823  are being planned_2696574  or conducted_22421850  at any_42344366  given time_17209466 .
Studies_17119574  may focus_2713938  on effective_4872674  means_1169254  of treatment_1650240 , better_4251307  ways_14873611  of treating_277958  the disease_113883821 , improving_2202884  the quality_of_life_113801064  for patients_110250423 , or appropriate_4152851  care_1648004  in remission_17318981  or after cures.
As of 1998 , it is estimated_2664380  that each_42346315  year_115004692 , approximately_37040  30 ,800  individuals_17626  will be diagnosed_2637804  with leukemia_114054437  in the United_States_18915715  and 21 ,700  individuals_17626  will die_2354455  of the disease_113883821 .
Tuberculosis_113955063  (abbreviated_2240551  as TB_113955063  for tubercle_bacillus_11360172  or Tuberculosis_113955063 ) is_22579744  a common_41010117  and deadly_41033542  infectious_disease_113938887  caused_21630835  by mycobacteria_11359986 , mainly_374239  Mycobacterium_tuberculosis_11360172 .
Tuberculosis_113955063  most_3112597  commonly_3107782  attacks_219756  the lungs_15322893  (as pulmonary_43019448  TB_113955063 ) but can also_347757  affect_219468  the central_nervous_system_15412828 , the lymphatic_system_15331715 , the circulatory_system_15442988 , the genitourinary_42966543  system_15174898 , bones_15206933 , joints_15525587  and even_317488  the skin_15175953 .
Other_42140352  mycobacteria_11359986  such as Mycobacterium bovis, Mycobacterium africanum, Mycobacterium canetti, and Mycobacterium microti can also_347757  cause_21630835  tuberculosis_113955063 , but these species_18000323  do not_324548  usually_3107782  infect_288912  healthy_41216552  adults_19469104 .
Over onethird_113556418  of the world_19138104  population_18066746  has been exposed_22092494  to the TB_113955063  bacterium_11332092 , and new_42141686  infections_113986195  occur_2336141  at a rate_115085533  of one_113561770  per second_115035938 .
Not_324548  everyone infected_42190227  develops_293465  the fullblown_4549761  disease_113883821 ; asymptomatic_42624567 , latent_440908  TB_113955063  infection_113986195  is_22579744  the most_3112597  common_41010117 .
However_328097 , one_42262724  in ten_42263664  latent_440908  infections_113986195  will progress to active_439766  TB_113955063  disease_113883821 , which, if left_2134595  untreated_42025631 , kills_21314030  more_than_41611077  half_113556027  of its victims_110591377 .
In 2004 , mortality_115076439  and morbidity_113645331  statistics_15943394  included_22607558  14 .6  million_113570444  chronic_447531  active_439766  TB_113955063  cases_19753021 , 8 .9  million_113570444  new_42141686  cases_19753021 , and 1 .6  million_113570444  deaths_17254694 , mostly_36130  in developing_countries_18054958 .
In_addition_346444 , a rising_42570453  number_15061203  of people_17834515  in the developed_41350180  world_19344389  are contracting_286898  tuberculosis_113955063  because their immune_systems_15393243  are compromised_21026104  by immunosuppressive_drugs_13523823 , substance_abuse_1934019 , or HIV_113991390 /AIDS_113939458 .
The rise_17224691  in HIV_11320298  infections_113986195  and the neglect_15636301  of TB_113955063  control_1792067  programs_15824218  have enabled_2507708  a resurgence_11033031  of tuberculosis_113955063 .
The emergence_17224447  of drug_13213810 resistant_41837465  strains_18000941  has also_347757  contributed_22531594  to this new_42141686  epidemic_17333958  with, from 2000  to 2004 , 20_42264613 % of TB_113955063  cases_19753021  being resistant_41837465  to standard_42373374  treatments_1650240  and 2_42262856 % resistant_41837465  to secondline drugs_13213810 .
TB_113955063  incidence_113645187  varies_22636971  widely_3498633 , even_317488  in neighboring_4468830  countries_18426193 , apparently_340662  because of differences_14692996  in health_care_11045595  systems_15828003 .


